APOP:NSD-Cellect Biotechnology Ltd (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 0.00

Change

0.00 (0.00)%

Market Cap

USD 0.01B

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


APOP Stock Forecast & Price:
Based on the Cellect Biotechnology Ltd stock forecasts from 0 analysts, the average analyst target price for Cellect Biotechnology Ltd is not available over the next 12 months. Cellect Biotechnology Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Cellect Biotechnology Ltd is Slightly Bearish, which is based on 1 positive signals and 2 negative signals. At the last closing, Cellect Biotechnology Ltd’s stock price was USD 0.00. Cellect Biotechnology Ltd’s stock price has changed by 0% over the past week, 0% over the past month and -100.00% over the last year.

No recent analyst target price found for Cellect Biotechnology Ltd
No recent average analyst rating found for Cellect Biotechnology Ltd

About Cellect Biotechnology Ltd (APOP:NSD)

As of October 28, 2021, Cellect Biotechnology Ltd. was acquired by Quoin Pharmaceuticals, Inc., in a reverse merger transaction. Cellect Biotechnology Ltd., a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enha ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-10 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

-3.06 (-1.02%)

USD75.25B 29.60 15.72
MRNA Moderna Inc

+3.13 (+1.83%)

USD71.57B 5.79 4.08
REGN Regeneron Pharmaceuticals Inc

+19.34 (+3.11%)

USD67.87B 12.49 9.34
BNTX BioNTech SE

+3.71 (+2.36%)

USD40.37B 3.26 2.01
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
SGEN Seagen Inc

+0.05 (+0.03%)

USD32.39B 55.02 -46.79
RPRX Royalty Pharma Plc

+0.25 (+0.57%)

USD29.52B 42.40 20.35
ALNY Alnylam Pharmaceuticals Inc

+8.63 (+3.86%)

USD27.16B N/A -34.32
GMAB Genmab AS

+0.56 (+1.59%)

USD22.96B 73.23 6.37
ARGX argenx NV ADR

+0.21 (+0.06%)

USD20.61B N/A -20.22

ETFs Containing APOP

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 42.61% 75% C 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 42.61% 75% C 84% B
Risk Return Profile  
Volatility (Standard Deviation) 154.06% 16% F 10% F
Risk Adjusted Return 27.66% 57% F 45% F
Market Capitalization 0.01B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 7.22 N/A N/A N/A N/A
Price / Cash Flow Ratio -0.83 N/A N/A N/A N/A
EV/EBITDA 0.19 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -120.42% N/A N/A N/A N/A
Return on Invested Capital -93.87% N/A N/A N/A N/A
Return on Assets -47.79% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 0.07 N/A N/A N/A N/A
Short Percent 8.32% N/A N/A N/A N/A
Beta 1.88 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.